(Q24235498)

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Clinical and conventional MRI predictors of disability and brain atrophy accumulation in RRMS. A large scale, short-term follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Long-term effects of glatiramer acetate in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Lobular panniculitis at the site of glatiramer acetate injections for the treatment of relapsing-remitting multiple sclerosis. A report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Development of Crohn's disease in a patient with multiple sclerosis treated with copaxone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

An urticarial vasculitis case induced by glatiramer acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Factors leading patients to discontinue multiple sclerosis therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Short-term combination of glatiramer acetate with i.v. steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

A longitudinal observational study of a cohort of patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Predictors of the location of multiple sclerosis relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Can glatiramer acetate reduce brain atrophy development in multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Tolerability, adverse events and compliance to glatiramer acetate in 28 patients with multiple sclerosis using the drug continuously for at least six months

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Copolymer 1 (glatiramer acetate) in relapsing forms of multiple sclerosis: open multicenter study of alternate-day administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Multiple sclerosis patients with anti-lipid oligoclonal IgM show early favourable response to immunomodulatory treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Co-operative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Long-term study of brain 1H-MRS study in multiple sclerosis: effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-Term H-MRS monitoring in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Interferon treatment may trigger primary headaches in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Glatiramer acetate-associated, CD30+, primary, cutaneous, anaplastic large-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

A post-marketing study on immunomodulating treatments for relapsing-remitting multiple sclerosis in Lombardia: preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Jessner-Kanof lymphocytic infiltration of the skin associated with glatiramer acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Severe anaphylactic reaction to glatiramer acetate with specific IgE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

State of the cervical section of the spinal cord in patients with remitting multiple sclerosis during immunomodulatory treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Multiple sclerosis and Capgras' syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Rapid Progression of Myelodysplastic Syndrome to Acute Myeloid Leukemia on Sequential Azathioprine, IFN-β and Copolymer-1 in a Patient with Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

The efficacy of glatiramer acetate in beta-interferon-intolerant MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Clinical and immune responses correlate in glatiramer acetate therapy of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Neuropsychologic status in multiple sclerosis after treatment with glatiramer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Combination therapy with interferon-beta and glatiramer acetate in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

New options for early treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Evidence for use of glatiramer acetate in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Evidence for use of glatiramer acetate in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Disability as an outcome in MS clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Lipoatrophy in patients with multiple sclerosis on glatiramer acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Lack of evidence for use of glatiramer acetate in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Surrogate endpoints in clinical trials: definition and operational criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Copolymer 1: from basic research to clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Chronic relapsing experimental allergic encephalomyelitis: an experimental model of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Beta blockade during and after myocardial infarction: an overview of the randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon β: Implications for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

A composite score to predict short-term disease activity in patients with relapsing-remitting MS

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

Localized lipoatrophy after glatiramer acetate injection in patients with remitting-relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

7 January 2021

Effect of glatiramer acetate (Copaxone) given orally in human patients: interleukin-10 production during a phase 1 trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

7 January 2021

Multiple sclerosis: trial of a synthetic polypeptide

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

7 January 2021

Experimental therapy of relapsing-remitting multiple sclerosis with copolymer-1

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

7 January 2021

Localized lipoatrophy after prolonged treatment with copolymer 1

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

7 January 2021

Necrotising cutaneous lesions as a side effect of glatiramer acetate

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

7 January 2021

Glatiramer acetate induced acute exacerbation of autoimmune hepatitis in a patient with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

7 January 2021

On cancer incidence in multiple sclerosis and effects of immunomodulatory treatments

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

7 January 2021

Effect of a synthetic polypeptide (COP 1) on patients with multiple sclerosis and with acute disseminated encephalomeylitis. Preliminary report

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

7 January 2021

Localized panniculitis secondary to subcutaneous glatiramer acetate injections for the treatment of multiple sclerosis: a clinicopathologic and immunohistochemical study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

7 January 2021

Benefits of glatiramer acetate on disability in relapsing-remitting multiple sclerosis. An analysis by area under disability/time curves. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

7 January 2021

Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

7 January 2021

Relapsing MS patients' experiences with glatiramer acetate treatment: a phenomenological study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

7 January 2021

Impact of warm compresses on local injection-site reactions with self-administered glatiramer acetate.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

7 January 2021

Impact of co-prescribed glatiramer acetate and antihistamine therapy on the likelihood of relapse among patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

7 January 2021

Immunomodulatory treatment of multiple sclerosis in Norway

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

7 January 2021

Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

7 January 2021

Erythema nodosum and glatiramer acetate treatment in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

7 January 2021

Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: multicenter study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

7 January 2021

Management of relapsing/remitting multiple sclerosis with copolymer 1 (Copaxone)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

7 January 2021

A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

7 January 2021

A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

7 January 2021

Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

7 January 2021

Extended use of glatiramer acetate (Copaxone) for MS

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

7 January 2021

Immunomodulatory treatment in multiple sclerosis: experience at a Brazilian center with 390 patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678.PUB2

7 January 2021